NCT04511533 - Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations | Biotech Hunter

Enrollment

101

Participants

Timeline

Start Date

August 27, 2020

Primary Completion Date

October 15, 2022

Study Completion Date

November 8, 2022

Conditions

Metastatic Non Small Cell Lung Cancer

Interventions

DRUG

Dacomitinib

Dacomitinib is a kinase inhibitor indicated for the first line treatment of patients with metastatic NSCLC with EGFR exon 19 deletion or exon 21 L858R substitution mutations.

Trial Locations (15)

110085

Rajiv Gandhi Cancer Institute And Research Centre, New Delhi

122001

Artemis hospital, Gurugram

380016

The Gujarat Cancer and Research Institute, Ahmedabad

380054

Hemato Oncology Clinic Ahmedabad Pvt. Ltd, Ahmedabad

395009

Gujarat Hospital - Gastro & Vascular Centre, Surat

Unity Trauma Center And ICU (Unity Hospital ), Surat

401107

Bhaktivedanta Hospital and Research Institute, Thāne

411001

Grant Medical Foundation, Ruby Hall Clinic, Pune

411004

Sahyadri Clinical Research and Development Center, Pune

Sahyadri Super Speciality Hospital, Pune

422009

Apex Wellness Hospital, Nashik

441108

National Cancer Institute, Nagpur

500082

Yashoda Hospital, Hyderabad

700094

Netaji Subhas Chandra Bose Cancer Hospital, Kolkata

700160

Tata Medical Center, Kolkata